
FLHLF
Healthcare · Drug Manufacturers - Specialty & Generic · $26,179 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2025 | Time not confirmed | — | -0.00 | — |
| Aug 19, 2025 | Time not confirmed | — | -0.00 | — |
| May 20, 2025 | Time not confirmed | — | -0.00 | — |
| Nov 29, 2024 | Time not confirmed | — | -0.00 | — |
| Aug 14, 2024 | Time not confirmed | — | -0.00 | — |
| May 16, 2024 | Time not confirmed | — | -0.00 | — |
| Nov 16, 2023 | Time not confirmed | — | -0.01 | — |
| Aug 16, 2023 | Time not confirmed | — | -0.01 | — |
| May 12, 2023 | Time not confirmed | — | -0.01 | — |
| Mar 31, 2023 | After the close | -0.02 | -0.07 | -250.0% |
| Nov 10, 2022 | After the close | -0.02 | -0.01 | +50.0% |
| Aug 15, 2022 | After the close | -0.01 | -0.01 | 0.0% |
| May 17, 2022 | After the close | -0.01 | -0.01 | 0.0% |
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provides in-house human…
| Mar 31, 2022 |
| After the close |
| -0.01 |
| -0.01 |
| 0.0% |
| Nov 15, 2021 | Before the open | — | -0.01 | — |